One-Year Clinical Outcomes of Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia: A Single-Center Experience of 52 Patients
Abstract
Introduction Water vapor thermal therapy (WVTT) has emerged as a minimally invasive surgical therapy (MIST) for benign prostatic hyperplasia (BPH) management. While international studies have confirmed its safety and efficacy, real-world data from Japanese outpatient clinics remain scarce. This study aimed to evaluate the one-year clinical outcomes of WVTT performed in a single urology clinic, representing the first Japanese single-center report describing one-year clinical outcomes of outpatient WVTT. Methods We conducted a retrospective cohort study at Mizuhodai Urology, including 52 patients who underwent WVTT between March 2023 and September 2024. Baseline and follow-up assessments at one, three, six, and 12 months included quality of life (QOL, International Prostate Symptom Score (IPSS)-QOL), prostate volume (PV), and postvoid residual (PVR) volume. Adverse events (AEs) were classified using the Clavien-Dindo system. Risk factors for the restart of BPH medication and failure of the first trial of void (TOV) were analyzed using multivariate logistic regression. Results Significant improvements in QOL, PV, and PVR were maintained throughout the 12-month follow-up period. All procedures were completed as day-case interventions under spinal anesthesia, with a median operative time of 3 min and a mean hospitalization duration of 259 min. Catheter removal was achieved in all patients, although the first TOV failed in seven cases. Restart of BPH medication was required in…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 52 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.